Thyroid gland follicular carcinoma

Summary

Thyroid gland follicular carcinoma (MONDO:0005034) is a cancer (an umbrella term covering 7 Mondo subtypes) with 3 cohort genes (3 CIViC-evidence somatic drivers) and 41 clinical trials. Molecularly, GNAS R201H confers sensitivity to Radioactive Iodine in Follicular Thyroid Carcinoma (CIViC Level C). Top therapeutic interventions include sunitinib, cabozantinib, and fludeoxyglucose f 18.

At a glance

• Classification: Cancer
• Umbrella term: 7 Mondo subtypes
• Cohort genes: 3
• Clinical trials: 41
• Precision-medicine evidence (CIViC): 1 subtype–drug association

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	thyroid gland follicular carcinoma
Mondo ID	MONDO:0005034
EFO	EFO:0000501
MeSH	D018263
DOID	DOID:3962
NCIT	C8054
SNOMED CT	255028004
UMLS	C0206682
MedGen	64630
GARD	0024144
Anatomy (UBERON)	UBERON:0005305
Is cancer (heuristic)	yes

Also known as: carcinoma of thyroid follicle · carcinoma, follicular cell, malignant · follicular adenocarcinoma · follicular adenocarcinoma (morphologic abnormality) · follicular adenocarcinoma, well differentiated · follicular adenocarcinoma, well differentiated (morphologic abnormality) · follicular cancer of the thyroid · follicular cancer of the thyroid gland · follicular cancer of thyroid · follicular cancer of thyroid gland · follicular carcinoma · follicular carcinoma of the thyroid · follicular carcinoma of the thyroid gland · follicular carcinoma of thyroid · follicular carcinoma of thyroid gland · follicular thyroid cancer · follicular thyroid carcinoma · follicular thyroid gland carcinoma · thyroid follicle carcinoma · thyroid follicular carcinoma (+5 more)

Data availability: 1 HPO phenotype · 19 cell lines.

Disease family

An umbrella term covering 7 Mondo subtypes.

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › endocrine gland neoplasm › thyroid tumor › thyroid cancer › thyroid gland carcinoma › differentiated thyroid carcinoma › thyroid gland follicular carcinoma

Related subtypes (2): thyroid gland papillary carcinoma, familial papillary or follicular thyroid carcinoma

Subtypes (7): trabecular follicular adenocarcinoma, thyroid gland papillary and follicular carcinoma, thyroid cancer, nonmedullary, 2, thyroid Hurthle cell carcinoma, thyroid cancer, nonmedullary, 4, thyroid cancer, nonmedullary, 5, medullary thyroid gland carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 22 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Somatic driver evidence (intOGen + CIViC, cohort fanout)

Gene	intOGen role	Cancer types	CIViC
GNAS	Act	BRCA,COADREAD,ESCA,HCC,LUAD,MBL,PAAD,PANCREAS	CIViC #2319
HRAS	Act	ANGS,BLCA,BRCA,COADREAD,CSCC,HNSC,LUSC,NPC,PGNG,PRAD,PROSTATE,THYM,UTUC,WDTC	CIViC #2747
NRAS	Act	ALL,AML,ANGS,CHOL,CLLSLL,COAD,COADREAD,GBM,HCC,LGGNOS,LUAD,LUSC,MEL,MGCT,NPC,OVT,PCM,PROSTATE,SKCM,THYM,UCEC,WDTC	CIViC #36

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
GNAS	Orphanet:189427	Cushing syndrome due to bilateral macronodular adrenocortical disease
GNAS	Orphanet:2762	Progressive osseous heteroplasia
GNAS	Orphanet:562	McCune-Albright syndrome
GNAS	Orphanet:57782	Mazabraud syndrome
GNAS	Orphanet:79443	Pseudohypoparathyroidism type 1A
GNAS	Orphanet:79444	Pseudohypoparathyroidism type 1C
GNAS	Orphanet:79445	Pseudopseudohypoparathyroidism
GNAS	Orphanet:93276	Polyostotic fibrous dysplasia
GNAS	Orphanet:93277	Monostotic fibrous dysplasia
GNAS	Orphanet:94089	Pseudohypoparathyroidism type 1B
HRAS	Orphanet:146	Differentiated thyroid carcinoma
HRAS	Orphanet:2612	Linear nevus sebaceus syndrome
HRAS	Orphanet:2874	Phakomatosis pigmentokeratotica
HRAS	Orphanet:3071	Costello syndrome
HRAS	Orphanet:79414	Woolly hair nevus
NRAS	Orphanet:146	Differentiated thyroid carcinoma
NRAS	Orphanet:2612	Linear nevus sebaceus syndrome
NRAS	Orphanet:268114	RAS-associated autoimmune leukoproliferative disease
NRAS	Orphanet:389	Langerhans cell histiocytosis
NRAS	Orphanet:626	Large/giant congenital melanocytic nevus
NRAS	Orphanet:648	Noonan syndrome
NRAS	Orphanet:86834	Juvenile myelomonocytic leukemia

Cohort genes → proteins

3 cohort genes, 3 distinct canonical proteins.

Evidence partition

Subset	Genes
civic_only	3

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
GNAS	HGNC:4392	ENSG00000087460	O95467	Neuroendocrine secretory protein 55	civic_evidence
HRAS	HGNC:5173	ENSG00000174775	P01112	GTPase HRas	civic_evidence
NRAS	HGNC:7989	ENSG00000213281	P01111	GTPase NRas	civic_evidence

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
HRAS	GTPase HRas	Involved in the activation of Ras protein signal transduction.
NRAS	GTPase NRas	Ras proteins bind GDP/GTP and possess intrinsic GTPase activity.

Protein-family classification

Druggable: 1 · Difficult: 0 · Unknown: 2 · Druggable fraction: 0.33

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Enzyme (other)	1	4.0×	0.460
Other/Unknown	2	1.2×	0.587

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
GNAS	Other/Unknown	no		NESP55, Gprotein_alpha_S, Gprotein_alpha_su
HRAS	Enzyme (other)	yes	3.6.5.2	Small_GTPase, Small_GTP-bd, Small_GTPase_Ras-type
NRAS	Other/Unknown	no		Small_GTPase, Small_GTP-bd, Small_GTPase_Ras-type

Expression context

Cohort genes with no expression data: 0.

3 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	3
unknown	0

Top tissues across cohort

Tissue	Cohort genes
Brodmann (1909) area 46	1
postcentral gyrus	1
type B pancreatic cell	1
skin of abdomen	1
skin of leg	1
zone of skin	1
epithelium of nasopharynx	1
gingival epithelium	1
secondary oocyte	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
GNAS	312	ubiquitous	marker	type B pancreatic cell, postcentral gyrus, Brodmann (1909) area 46
HRAS	139	ubiquitous	marker	skin of abdomen, skin of leg, zone of skin
NRAS	278	ubiquitous	marker	gingival epithelium, epithelium of nasopharynx, secondary oocyte

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
HRAS	8,064
NRAS	7,598
GNAS	410

Structural data

PDB: 3 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
GNAS	O95467	490
HRAS	P01112	246
NRAS	P01111	35

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 82. Enrichment computed across 3 evidence-associated genes (3 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Signaling by RAS GAP mutants	2	2537.8×	6e-06	HRAS, NRAS
Signaling by RAS GTPase mutants	2	2537.8×	6e-06	HRAS, NRAS
Activation of RAS in B cells	2	1522.7×	1e-05	HRAS, NRAS
RAS signaling downstream of NF1 loss-of-function variants	2	1087.6×	2e-05	HRAS, NRAS
Estrogen-stimulated signaling through PRKCZ	2	1087.6×	2e-05	HRAS, NRAS
SOS-mediated signalling	2	951.7×	2e-05	HRAS, NRAS
Activated NTRK3 signals through RAS	2	845.9×	2e-05	HRAS, NRAS
EGFR Transactivation by Gastrin	2	761.3×	2e-05	HRAS, NRAS
SHC-related events triggered by IGF1R	2	761.3×	2e-05	HRAS, NRAS
Activated NTRK2 signals through RAS	2	761.3×	2e-05	HRAS, NRAS
MET activates RAS signaling	2	692.1×	2e-05	HRAS, NRAS
Signaling by FGFR4 in disease	2	634.4×	2e-05	HRAS, NRAS
Activated NTRK2 signals through FRS2 and FRS3	2	634.4×	2e-05	HRAS, NRAS
Constitutive Signaling by Overexpressed ERBB2	2	634.4×	2e-05	HRAS, NRAS
p38MAPK events	2	585.6×	2e-05	HRAS, NRAS
Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants	2	585.6×	2e-05	HRAS, NRAS
Signaling by PDGFRA extracellular domain mutants	2	585.6×	2e-05	HRAS, NRAS
PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases	2	543.8×	2e-05	HRAS, NRAS
GRB2 events in EGFR signaling	2	507.6×	2e-05	HRAS, NRAS
Erythropoietin activates RAS	2	507.6×	2e-05	HRAS, NRAS
Signaling by FLT3 ITD and TKD mutants	2	507.6×	2e-05	HRAS, NRAS
SHC1 events in ERBB4 signaling	2	475.8×	2e-05	HRAS, NRAS
SHC1 events in EGFR signaling	2	475.8×	2e-05	HRAS, NRAS
Constitutive Signaling by EGFRvIII	2	475.8×	2e-05	HRAS, NRAS
Signalling to RAS	2	447.8×	2e-05	HRAS, NRAS
Insulin receptor signalling cascade	2	447.8×	2e-05	HRAS, NRAS
Signaling by ERBB2 ECD mutants	2	447.8×	2e-05	HRAS, NRAS
GRB2 events in ERBB2 signaling	2	423.0×	2e-05	HRAS, NRAS
Tie2 Signaling	2	400.7×	2e-05	HRAS, NRAS
SHC-mediated cascade:FGFR3	2	400.7×	2e-05	HRAS, NRAS

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
Ras protein signal transduction	2	137.0×	0.005	HRAS, NRAS
MAPK cascade	2	102.1×	0.005	HRAS, NRAS
adenylate cyclase-activating G protein-coupled bile acid receptor signaling pathway	1	1872.4×	0.009	GNAS
positive regulation of miRNA metabolic process	1	1872.4×	0.009	HRAS
response to parathyroid hormone	1	1404.3×	0.009	GNAS
adenylate cyclase-activating serotonin receptor signaling pathway	1	1123.5×	0.009	GNAS
hair follicle placode formation	1	1123.5×	0.009	GNAS
regulation of skeletal muscle contraction	1	936.2×	0.009	GNAS
cellular response to catecholamine stimulus	1	802.5×	0.009	GNAS
oncogene-induced cell senescence	1	802.5×	0.009	HRAS
T-helper 1 type immune response	1	624.1×	0.011	HRAS
adenylate cyclase-activating dopamine receptor signaling pathway	1	510.7×	0.011	GNAS
intracellular transport	1	510.7×	0.011	GNAS
response to prostaglandin E	1	468.1×	0.011	GNAS
adenylate cyclase-activating adrenergic receptor signaling pathway	1	401.2×	0.011	GNAS
activation of adenylate cyclase activity	1	374.5×	0.011	GNAS
sensory perception of chemical stimulus	1	374.5×	0.011	GNAS
negative regulation of multicellular organism growth	1	374.5×	0.011	GNAS
Schwann cell development	1	351.1×	0.011	HRAS
regulation of long-term neuronal synaptic plasticity	1	330.4×	0.011	HRAS
positive regulation of ruffle assembly	1	330.4×	0.011	HRAS
regulation of neurotransmitter receptor localization to postsynaptic specialization membrane	1	295.6×	0.011	HRAS
cellular response to glucagon stimulus	1	280.9×	0.011	GNAS
cellular response to prostaglandin E stimulus	1	280.9×	0.011	GNAS
developmental growth	1	244.2×	0.012	GNAS
cellular response to acidic pH	1	244.2×	0.012	GNAS
vascular endothelial cell response to laminar fluid shear stress	1	244.2×	0.012	GNAS
negative regulation of inflammatory response to antigenic stimulus	1	200.6×	0.013	GNAS
defense response to protozoan	1	200.6×	0.013	HRAS
cellular response to gamma radiation	1	200.6×	0.013	HRAS

Therapeutics

Drugs indicated for this disease

No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Aflibercept, Bortezomib, Cabozantinib, Dabrafenib, Decitabine, Durvalumab, Lenvatinib, Pembrolizumab, Romidepsin, Selpercatinib, Selumetinib, Sorafenib, Tanespimycin, Thyrotropin, Thyrotropin Alfa, Trametinib, Tremelimumab, Vandetanib, Vorinostat.

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 2 · Undrugged: 1

Druggability breadth: 3 of 3 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
HRAS	LONAFARNIB

Top cohort targets by molecule count

Symbol	Molecules	Max phase
HRAS	4	4
NRAS	1	1
GNAS	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
LONAFARNIB	4	HRAS
STALLIMYCIN	2	HRAS
L-778123 FREE BASE	1	HRAS, NRAS
BMS-214662	1	HRAS

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
HRAS	48	Binding:45, Functional:3
NRAS	18	Binding:18

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
HRAS	3.6.5.2	small monomeric GTPase

Pharmacogenomics

Cohort genes with a PharmGKB record: 3; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Drug repurposing candidates

4 approved/phased drugs hit cohort targets but don’t yet appear in disease-level clinical trials. Target-inhibition rationale is strongest for cancer driver genes; a bioactivity hit is a screening signal, not a treatment claim.

Compound	Max phase	Cohort target (bioactivity)
LONAFARNIB	4	HRAS
STALLIMYCIN	2	HRAS
L-778123 FREE BASE	1	HRAS, NRAS
BMS-214662	1	HRAS

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	1	HRAS
B	Phased (≥1) drug, not yet approved	1	NRAS
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	1	GNAS

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
GNAS	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 41.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	23
Not specified	12
PHASE1	5
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02152995	PHASE2	ACTIVE_NOT_RECRUITING	Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer
NCT03914300	PHASE2	ACTIVE_NOT_RECRUITING	Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer
NCT04544111	PHASE2	ACTIVE_NOT_RECRUITING	PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
NCT05668962	PHASE2	RECRUITING	Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
NCT06440850	PHASE2	RECRUITING	Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation
NCT06959641	PHASE2	RECRUITING	XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer
NCT00085293	PHASE2	COMPLETED	Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131
NCT00095693	PHASE2	TERMINATED	Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer
NCT00098813	PHASE2	COMPLETED	Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine
NCT00104871	PHASE2	COMPLETED	Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
NCT00118248	PHASE2	COMPLETED	Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer
NCT00134043	PHASE2	COMPLETED	Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer
NCT00381641	PHASE2	COMPLETED	Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery
NCT00519896	PHASE2	COMPLETED	Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer
NCT00668811	PHASE2	COMPLETED	Sutent Adjunctive Treatment of Differentiated Thyroid Cancer
NCT00729157	PHASE2	COMPLETED	Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
NCT01208051	PHASE1/PHASE2	COMPLETED	Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer
NCT01723202	PHASE2	COMPLETED	Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer
NCT01811212	PHASE2	COMPLETED	Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
NCT02393690	PHASE2	COMPLETED	Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer
NCT02973997	PHASE2	COMPLETED	Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)
NCT03506048	PHASE2	TERMINATED	Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer
NCT03630120	PHASE2	TERMINATED	Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer
NCT03753919	PHASE2	TERMINATED	Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial
NCT00004074	PHASE1	COMPLETED	Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
NCT00470496	PHASE1	COMPLETED	Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer
NCT01100619	PHASE1	COMPLETED	A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors
NCT01413113	PHASE1	COMPLETED	Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery
NCT05410821	PHASE1	COMPLETED	Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Metastatic Radioactive Iodine Refractory Thyroid Cancer
NCT00001160	Not specified	RECRUITING	Studies on Tumors of the Thyroid
NCT04948437	Not specified	ACTIVE_NOT_RECRUITING	Urinary Exosomal Biomarkers of Thyroglobulin and Galectin-3 for Prognosis and Follow-up in Patients of Thyroid Cancer
NCT05463107	Not specified	ACTIVE_NOT_RECRUITING	Correlation Between Various Urinary Exosomal Protein Biomarkers and Pathological Manifestation in Thyroid Follicular Neoplasm: Early and Pre-operative Diagnosis of Follicular Thyroid Cancer
NCT05575440	Not specified	RECRUITING	Evaluation of 18F-TFB PET/CT Scan in Patients With Differentiated Thyroid Cancer
NCT07529080	Not specified	NOT_YET_RECRUITING	Personalized Cancer Support (Thrive Track) to Manage the Emotional Needs of Young Adults With Thyroid, Melanoma and Testicular Cancer, PerCS-YA Trial
NCT07545837	Not specified	NOT_YET_RECRUITING	Health and Wellness Coaching to Improve Adherence to Healthy Habits and Treatment Plans in Papillary and Follicular Thyroid Cancer Survivors
NCT00068497	Not specified	COMPLETED	Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer
NCT01441154	Not specified	COMPLETED	Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer Treatment
NCT03639662	Not specified	UNKNOWN	Psychological Impact of a Sophrological Accompaniment During the Announcement of Thyroid Cancer
NCT05052359	Not specified	COMPLETED	Aberrant Helix Pomatia Agglutinin Binding Glycan Expression in Follicular Thyroid Tumours
NCT05591092	Not specified	COMPLETED	Radioiodine Planar and a SPECT/CT Imaging With Iodine-123 for Evaluation of Follicular Thyroid Nodules Prior to Surgery

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
SUNITINIB	4	9
CABOZANTINIB	4	7
FLUDEOXYGLUCOSE F 18	4	3
SORAFENIB	4	3
DABRAFENIB	4	2
LENVATINIB	4	2
TRAMETINIB	4	2
COBIMETINIB	4	1
DECITABINE	4	1
PAZOPANIB HYDROCHLORIDE	4	1
ROMIDEPSIN	4	1
SELPERCATINIB	4	1
SELUMETINIB	4	1
TRASTUZUMAB	4	1
VANDETANIB	4	1
VEMURAFENIB	4	1
VORINOSTAT	4	1
IODINE	3	4
CEDIRANIB	3	3
SPARTALIZUMAB	3	1
TANESPIMYCIN	3	1
ZANZALINTINIB	3	1
EDODEKIN ALFA	2	1
HPPH	2	1
CHEMBL5433950	0	3
CHEMBL4066465	0	1
CHEMBL4786163	0	1
CHEMBL275117	0	1
CHEMBL4517714	0	1
CHEMBL5405436	0	1

Precision-medicine subtype map (CIViC)

Drug × molecular subtype: 1 predictive associations from 1 curated evidence items; also 4 prognostic, 1 diagnostic.

Molecular subtype	Therapy	Effect	Level	CIViC
GNAS R201H	Radioactive Iodine	Sensitivity/Response	CIViC C	EID3045